Objective:To evaluate the clinical efficacy of Tiapride Hydrochloride Tablets combined with Shaoma Zhijing Granules in treating children with tic disorders.Method:This prospective,randomized controlled trial was conducted at People's Hospital of Ruijin City from February 2022 to July 2024,involving 102 children with tic disorders.Participants were randomly divided into control group(51 cases)and an experimental group(51 cases)at a 1:1 ratio.The control group received Tiapride Hydrochloride Tablets treatment,while the experimental group received a combination of Tiapride Hydrochloride Tablets and Shaoma Zhijing Granules.Tic symptoms[Yale global tic severity scale(YGTSS)score],traditional Chinese medicine syndrome scores,behavior and intelligence[Achenbach child behavior checklist(CBCL)score and Wechsler intelligence scale for children score],the levels of neurotransmitter[dopamine(DA),norepinephrine(NE),and brain-derived neurotrophic factor(BDNF)],and adverse reactions(loss of appetite,dizziness and fatigue,drowsiness,rash,diarrhea)were compared between the two groups.Result:After treatment,the experimental group showed lower YGTSS scores and traditional Chinese medicine syndrome scores than the control group(P<0.05).The experimental group also had lower CBCL score and higher Wechsler intelligence scale scores than the control group(P<0.05).The levels of DA and NE were lower,while BDNF levels were higher in the experimental group compared to the control group(P<0.05).The total rate of adverse reactions in the experimental group was lower than that in the control group(P<0.05).Conclusion:The combined use of Tiapride Hydrochloride Tablets and Shaoma Zhijing Granules in treating children with tic disorders is effective in improving tic symptoms,behavior and intelligence performance,and optimizing neurotransmitter levels,while reducing adverse reactions,it is a safe and effective treatment option.
关键词
盐酸硫必利片/芍麻止痉颗粒/儿童抽动障碍/神经递质水平
Key words
Tiapride Hydrochloride Tablets/Shaoma Zhijing Granules/Children with tic disorders/Neurotransmitter levels